Agios Pharmaceuticals Inc (NASDAQ: AGIO) is 103.68% higher on its value in year-to-date trading and has touched a low of $19.80 and a high of $50.35 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AGIO stock was last observed hovering at around $47.09 in the last trading session, with the day’s loss setting it -1.73%.
Currently trading at $45.36, the stock is 1.07% and 0.75% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.88 million and changing -3.67% at the moment leaves the stock 38.47% off its SMA200. AGIO registered 68.31% gain for a year compared to 6-month gain of 34.72%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -3.06% loss in the last 1 month and extending the period to 3 months gives it a 19.37%, and is -3.69% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.05% over the week and 4.62% over the month.
Agios Pharmaceuticals Inc (AGIO) has around 383 employees, a market worth around $2.58B and $31.31M in sales. Profit margin for the company is -1165.69%. Distance from 52-week low is 129.15% and -9.91% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.45%).
Agios Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -1.01 with sales reaching $9.9M over the same period.The EPS is expected to grow by 21.96% this year, but quarterly earnings will post 42.00% year-over-year. Quarterly sales are estimated to grow 31.60% in year-over-year returns.
298.0 institutions hold shares in Agios Pharmaceuticals Inc (AGIO), with institutional investors hold 105.68% of the company’s shares. The shares outstanding are 55.95M, and float is at 55.15M with Short Float at 6.27%. Institutions hold 104.04% of the Float.
The top institutional shareholder in the company is FARALLON CAPITAL MANAGEMENT LLC with over 5.65 million shares valued at $243.82 million. The investor’s holdings represent 9.9547 of the AGIO Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 5.5 million shares valued at $237.02 million to account for 9.6769 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 4.86 million shares representing 8.5542 and valued at over $209.52 million, while BELLEVUE GROUP AG holds 6.8299 of the shares totaling 3.88 million with a market value of $167.29 million.
Agios Pharmaceuticals Inc (AGIO) Insider Activity
The most recent transaction is an insider sale by Goff Brian, the company’s Chief Executive Officer. SEC filings show that Goff Brian sold 11,091 shares of the company’s common stock on Aug 08 ’24 at a price of $42.75 per share for a total of $0.47 million. Following the sale, the insider now owns 78792.0 shares.
Still, SEC filings show that on Jul 01 ’24, Gheuens Sarah (Chief Medical Officer) disposed off 3,705 shares at an average price of $43.85 for $0.16 million. The insider now directly holds 43,736 shares of Agios Pharmaceuticals Inc (AGIO).
